RxDoctor Payments DataLook up a doctor →

Nitin Gupta, MD

Gastroenterology · Atlanta, GANPI 1013113364

Payments from drug & device makers

$1,655,453in general payments, 2019–2025

Across 1,324 payments — averaging $1250.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$514K
  • Janssen Research & Development, LLC$286K
  • Johnson & Johnson$217K
  • E.r. Squibb & Sons, L.L.C.$142K
  • Janssen Scientific Affairs, LLC$125K
  • Roche Products Limited$96K
  • plus $274K from 34 others

What the payments were for

  • Consulting fees$4,2000%
  • Speaking & faculty fees$950,83489%
  • Travel & lodging$92,7039%
  • Food & beverage$23,0472%
  • Education$5150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,655,453 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$82,104
Medicare patients
286
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab245$6,689,898
Humira(Cf) PenAdalimumab87$710,569
Skyrizi On-BodyRisankizumab-Rzaa29$627,628
RinvoqUpadacitinib66$566,977
Cimzia (2 Pack)Certolizumab Pegol19$119,812
CreonLipase/Protease/Amylase11$41,922
Mesalamine49$37,325
LinzessLinaclotide28$31,485
Balsalazide Disodium197$24,744
Mesalamine ErMesalamine57$17,266
Pantoprazole Sodium407$5,943
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates75$5,044
Sulfasalazine109$3,937
Budesonide DrBudesonide20$3,727
Esomeprazole Magnesium31$3,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$217,093$6,689,898245 claims
AbbVieRinvoq, Creon, Linzess$514,121$640,385105 claims
UCB, Inc.Cimzia (2 Pack)$30$119,81219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →